Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04495452
Other study ID # IRB-300004738
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date June 10, 2024
Est. completion date September 1, 2025

Study information

Verified date December 2023
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is designed to look at how often a decrease in the rate of breathing occurs after being given a routinely used intravenous (IV) pain medication. This pain medication (Fentanyl) is given in the research procedure room by the anesthesiologist. In addition to relieving pain, in some patients it has been observed that this medication may decrease the rate of breathing. Different pieces of one's genetic makeup (also known as genes) can affect how well this medication relieves pain. The investigators do not know if these same genes influence how large the effect of the medication has on breathing rate. The purpose of this study is to determine if the presence or alteration of these same genes may be associated with a decrease in rate of breathing.


Description:

Opioids are key analgesic drugs. Unfortunately, they have a high potential for abuse with potentially lethal consequences, more specifically death due to respiratory suppression. In both Canada and the US, the number of deaths from opioid overdose continues to rise at an alarming rate, far exceeding fatalities from motor vehicle accidents in Canada and becoming the number one cause of unintentional injury-related death in the US. In light of the opioid epidemic and CDC-scrutiny of opioid use, determining genetic profiles susceptible to respiratory depression could prove useful in further tailoring the treatment of pain both in the perioperative setting and in the chronic pain management setting. The purpose of the proposed study is to evaluate for a genetic component of opioid-induced respiratory depression. Our overall study hypothesis is that genetic variation influences opioid-induced respiratory depression. The primary aim of the study is to correlate an intravenous opioid bolus and genetic variations of opioid-related target genes. Secondary aims or outcomes are the determination of general variation in respiratory responses in response to a single intravenous fentanyl bolus. Other observed effects are age and gender related differences, the effect of a single fentanyl bolus on alertness, the incidence of emesis and opioid effects on micturition as determined by the modified Aldrete discharge criteria. Based on existing work on genetic determinants of opioid receptor effects, we propose to correlate clinical parameters of respiratory depression (proportional reduction in respiratory minute ventilation) with the expression of single-nucleotide polymorphisms (SNPs) of genes related to opioid-induced analgesia. We propose to identify a subset of participants with the most significant respiratory depression and contrast those with participants that exhibit no respiratory effects. The blood samples from these two groups will be used to compare genetic variances of genes related to opioid-induced analgesia. This will be a collaborative project between the clinical physicians and basic scientists in an effort to better characterize opioid-induced respiratory depression. We believe this work will be valuable as a means to prevent and treat opioid toxicity and guide development of safer approaches to opioid therapy and drug development.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 1, 2025
Est. primary completion date December 10, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 40 Years
Eligibility Inclusion Criteria: - Healthy Subjects - older than 19 - able to follow the study instructions Exclusion Criteria: - Any medical condition that could affect study procedures or potentially put the subject at risk, in the opinion of the investigators - age less than 18 or older than 40 - pregnancy - obesity - sleep apnea - pulmonary problems such as moderate or severe bronchial asthma - epilepsy - chronic analgesic medication - history of surgery for which details are unavailable - allergy to fentanyl - history of drug abuse - positive urine test for illicit drugs - female participants will be scheduled for a urine pregnancy test on the day of the procedure, prior to receiving study medication, only subjects with negative tests will continue

Study Design


Intervention

Drug:
Fentanyl Drug Administration
Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Outcome

Type Measure Description Time frame Safety issue
Primary Respiratory rate A decrease in breathing frequency as quantified by respiratory rate From the time of administration of study medication to 10 minutes after study medication administration
Primary Minute Ventilation A decrease in breathing as quantified by minute ventilation From the time of administration of study medication to 10 minutes after study medication administration
Primary Occlusion Pressure A measure of respiratory depression as quantified by occlusion pressure From the time of administration of study medication to 10 minutes after study medication administration
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03441282 - Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression
Completed NCT02907255 - Vital Sign Monitoring With Continuous Pulse Oximetry and Wireless Clinician Notification After Surgery N/A
Completed NCT00544947 - Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids for Caesarean Section N/A
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05391555 - Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age Phase 2/Phase 3
Completed NCT02481570 - Anesthetic Optimization in Scoliosis Surgery N/A
Completed NCT06083272 - VitalThings Guardian Contactless Monitoring
Not yet recruiting NCT06064409 - Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
Completed NCT00345384 - Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients Phase 1/Phase 2
Recruiting NCT04046068 - Multimodal Perioperative Pain Management: ComfortSafe Program
Recruiting NCT02819661 - Respiratory Depression in Women With BMI≥30 Underwent Spinal Anesthesia With Intrathecal Morphine in Elective C-section N/A
Active, not recruiting NCT04011163 - Vital Signs-Integrated Patient-Assisted Intravenous Opioid Analgesia for Post Surgical Pain Phase 2/Phase 3
Active, not recruiting NCT06374589 - Closed-Loop O2 Use During High Flow Oxygen Treatment Of Critical Care Adult Patients (CLOUDHFOT) N/A
Terminated NCT02760927 - Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes N/A
Completed NCT01869582 - Safer Births - Reducing Perinatal Mortality N/A
Completed NCT00875134 - Testing of the Apnea Prevention Device Phase 1/Phase 2
Not yet recruiting NCT06137638 - ENA-001 for Post Operative Respiratory Depression (PORD) Phase 2
Completed NCT01843933 - Detecting Post-Operative Respiratory Depression in Children N/A
Completed NCT00696137 - Long-term Extension Study of BEMA™ Fentanyl Phase 3
Completed NCT04017702 - Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring